Two compounds, bromovinyldeoxyuridine ([E]-5-[2-bromovinyl]-2'-deoxyuridine) and trifluridine (5-trifluoromethyl-2' deoxyuridine) were compared for their efficacy in the topical treatment of experimental stroma herpetic keratitis produced by the injection of live herpes simplex virus, type 1, into the corneal stroma of rabbits. The trifluridine was used as 1% eyedrops, whereas bromovinyldeoxyuridine was used as either 0.1% or 0.5% eyedrops. All three treatment regimens caused a substantial healing of stroma disease in comparison with placebo treatment. The bromovinyldeoxyuridine (whether used as 0.1% or 0.5%) proved superior to 1% trifluridine eyedrops when the treatment was started one day after virus inoculation. However, bromovinyldeoxyuridine and trifluridine were equally effective if the treatment was started seven days after infection. The 0.5% bromovinyldeoxyuridine eyedrops seemed to be more effective in controlling the complicating severe iritis and secondary glaucoma than either 0.1% bromovinyldeoxyuridine or 1% trifluridine. No toxic effects were observed with bromovinyldeoxyuridine in any eye, whereas 1% trifluridine produced punctate epitheliopathy in some eyes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1001/archopht.1982.01030030655027 | DOI Listing |
Curr Eye Res
January 2005
Department of Clinical Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, United Kingdom.
Purpose: To determine, by a plaque reduction assay, the in vitro efficacy of novel antiviral agents in the treatment of feline herpes virus 1 (FHV-1) keratitis in the domestic cat (Felis felis).
Materials And Methods: A standard plaque reduction assay was performed using a laboratory strain of FHV-1 and embryo-derived feline kidney cells to determine the in vitro efficacy of the antiviral drugs penciclovir (PCV), bromovinyldeoxyuridine (BVdU), and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine (HPMPA) and to compare these with the drugs acyclovir (ACV) and trifluorothymidine (TFT). Efficacy was assessed by determining the dose of drug at which 50% plaque reduction was noted (ED(50)).
Can J Ophthalmol
August 1995
Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Objective: To evaluate the efficacy of four antiviral agents--1% idoxuridine ointment (group 1), 2% trifluorothymidine ointment (group 2), 3% acyclovir ointment (group 3) and 1% bromovinyldeoxyuridine (BVDU) ointment (group 4)--in herpes simplex keratitis.
Design: Randomized double-blinded clinical trial.
Setting: Tertiary care institution in New Delhi.
Br J Ophthalmol
November 1991
Professorial Unit, Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
The results of a randomised double-blind clinical trial of 0.1% bromovinyldeoxyuridine (BVDU) and 1% trifluorothymidine (TFT) in 60 patients with corneal dendritic ulceration are presented. There was no significant difference between BVDU and TFT in terms of numbers of ulcers healed (p = 0.
View Article and Find Full Text PDFFifty patients with corneal dendritic ulceration were randomly entered into a double blind clinical trial comparing BVDU eyedrops with TFT eyedrops. Of those receiving TFT 100% healed in a mean time of 6.7 days, while 92% of those receiving BVDU healed in a mean time of 8.
View Article and Find Full Text PDFCurr Eye Res
September 1991
Eye Research Laboratory, Katholieke Universiteit Leuven, Belgium.
Patients suffering from dendritic and geographic corneal ulcers or herpetic stromal keratitis were treated with topical BVDU [(E)-5-(2-bromovinyl)-2'-deoxyuridine, bromovinyldeoxyuridine] 0.1% eyedrops administered during the day only at 1-hour intervals. Treatment with other antiviral drugs, i.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!